Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771879 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL31125745 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL2582084 | 0.84 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1NPSR1LMNAMEN1 | |
| SCHEMBL2582091 | 0.84 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1NPSR1LMNAMEN1 | |
| SCHEMBL13314540 | 0.83 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL24859803 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL20583509 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL26110369 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL8777208 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL22983337 | 0.80 | LMNA (0.54) | SMN1; SMN2ALDH1A1RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | disclosed |
| EP-4275756-A2 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | SMN1; SMN2 4762/4885ALDH1A1 4008/4885RAB9A 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.